Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 11 (2022) > Article

DOI: 10.14704/nq.2022.20.11.NQ66124

PRODUCT DEVELOPMENT AND EVALUATION OF FLOATING PELLETS OF RANITIDINE HYDROCHLORIDE FOR THE TREATMENT OF GASTRIC ULCER

Mohamed Yasik M, Lokshana.D, Gayathri.H*, Damodharan.N

Abstract

The aim is to develop floating matrix pellets of Ranitidine Hydrochloride to achieve gastric retention for a period of 12 hour. Ranitidine HCL is a H2 - receptor antagonist widely prescribed in gastric ulcer, duodenal ulcers, Zollinger Ellison syndrome and gastro-oesophageal reflex. Ranitidine HCL has shorter half-life of 1-2 hours, in order to improve the oral sustained delivery there is a need for the design sustained release dosage. Since Ranitidine Hydrochloride is having a very short half life and also mostly absorbed (absorption window) in the stomach and upper part of small intestine. Hence ranitidine hydrochloride is suitable for gastro retentive drug delivery system (GRDD’S). The sustained release helps in continuous release of drug thus ensuring optimal bioavailability of the drug which favors development of floating matrix dosage form. The effervescent floating system helps in increasing stomach site bioavailability and efficacy of drug to reduce acid secretion

Keywords

pellets, buoyancy, ulcer, retention

Full Text

PDF

References

?>